公开(公告)号：US20170049740A1

公开(公告)日：2017-02-23

申请号：US15346926

申请日：2016-11-09

Applicant: ITALFARMACO SPA

Inventor： Tiziano OLDONI ,  Paolo MASCAGNI ,  Alessandro RAMBALDI ,  Tiziano BARBUI

IPC: A61K31/27 ,  A61K45/06

CPC classification number: A61K31/27 ,  A61K31/00 ,  A61K31/16 ,  A61K31/167 ,  A61K31/18 ,  A61K45/06

Abstract: The use of substances capable of inhibiting one or more enzymes of the histone deacetylase family (histone deacetylase inhibitors) for the therapeutic treatment of Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis) is described. The dosage of the above-mentioned substances is significantly lower than that normally used for the care of other tumour syndromes and may be from 10 to 150 mg/day/patient.

Abstract translation: 描述了能够抑制组蛋白脱乙酰酶家族的一种或多种酶（组蛋白脱乙酰酶抑制剂）用于费城阴性骨髓增生综合征（真性红细胞增多症，原发性血小板增多症或特发性骨髓纤维化）的治疗性治疗的物质的使用。 上述物质的剂量明显低于通常用于其他肿瘤综合征的治疗剂量，并且可以为10至150mg /天/患者。

公开(公告)号：US20210128512A1

公开(公告)日：2021-05-06

申请号：US17149794

申请日：2021-01-15

Applicant: ITALFARMACO SPA

Inventor： Tiziano OLDONI ,  Paolo MASCAGNI ,  Alessandro RAMBALDI ,  Tiziano BARBUI

IPC: A61K31/27 ,  A61K31/00 ,  A61K31/16 ,  A61K31/18 ,  A61K31/167 ,  A61K45/06

Abstract: Method of treating Philadelphia-negative myeloproliferative syndromes in a patient suffering therefrom by administering to the patient diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates, in a daily dosage amount of from 50 to 100 mg per patient.